Morgan Stanley Maintains Overweight on Ventyx Biosciences, Raises Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Simon Flannery has maintained an Overweight rating on Ventyx Biosciences (NASDAQ:VTYX) and raised the price target from $45 to $46.
August 29, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained an Overweight rating on Ventyx Biosciences and raised the price target from $45 to $46, which could positively impact the stock's price.
The Overweight rating maintained by Morgan Stanley indicates a positive outlook for Ventyx Biosciences. The increase in the price target from $45 to $46 suggests that the analyst sees potential for the stock's price to rise, which could lead to a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100